FDA
- Status: approved
No oral drug therapy throughout the pollen period (No oral drug therapy throughout the pollen period) regulatory status in United States.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. FDA has authorised it.
Beijing Tongren Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.